These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 19897532)

  • 21. [Public clinical trials: which kind of monitoring should be used?].
    Cornu C; Binquet C; Thalamas C; Vigouroux C; Gaillard S; Ginhoux T; Vaz B; Jossan C; Félin A; Sailly A; Gueyffier F; Journot V; Kassaï B
    Therapie; 2013; 68(3):135-41. PubMed ID: 23886457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microstream capnography improves patient monitoring during moderate sedation: a randomized, controlled trial.
    Lightdale JR; Goldmann DA; Feldman HA; Newburg AR; DiNardo JA; Fox VL
    Pediatrics; 2006 Jun; 117(6):e1170-8. PubMed ID: 16702250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a checklist of quality indicators for clinical trials in resource-limited countries: the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience.
    Hanna M; Minga A; Fao P; Borand L; Diouf A; Mben JM; Gad RR; Anglaret X; Bazin B; Chene G;
    Clin Trials; 2013 Apr; 10(2):300-18. PubMed ID: 23345311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Planning and core analyses for periodic aggregate safety data reviews.
    Xia HA; Crowe BJ; Schriver RC; Oster M; Hall DB
    Clin Trials; 2011 Apr; 8(2):175-82. PubMed ID: 21270142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A statistical approach to central monitoring of data quality in clinical trials.
    Venet D; Doffagne E; Burzykowski T; Beckers F; Tellier Y; Genevois-Marlin E; Becker U; Bee V; Wilson V; Legrand C; Buyse M
    Clin Trials; 2012 Dec; 9(6):705-13. PubMed ID: 22684241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Participants' perspectives on safety monitoring in clinical trials.
    Flynn KE; Kramer JM; Dombeck CB; Weinfurt KP
    Clin Trials; 2013 Aug; 10(4):552-9. PubMed ID: 23644503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failsafe automation of Phase II clinical trial interim monitoring for stopping rules.
    Day RS
    Clin Trials; 2010 Feb; 7(1):78-84. PubMed ID: 20156959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Data monitoring committees. Third pillar in the methodical conduct of clinical trials].
    Fischer T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):793-6. PubMed ID: 18563280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Patient safety in clinical intervention research].
    Brekelmans CT; Kenter MJ; Bouter LM; Koëter GH
    Ned Tijdschr Geneeskd; 2011; 155():A2359. PubMed ID: 21342593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study.
    Journot V; Pignon JP; Gaultier C; Daurat V; Bouxin-Métro A; Giraudeau B; Preux PM; Tréluyer JM; Chevret S; Plättner V; Thalamas C; Clisant S; Ravaud P; Chêne G;
    Contemp Clin Trials; 2011 Jan; 32(1):16-24. PubMed ID: 20951234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality assurance in clinical trials.
    Feigenbaum SL
    Semin Reprod Endocrinol; 1996 May; 14(2):93-100. PubMed ID: 8796931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [DSMB. 1. What role, what responsibilities?].
    Brun-Buisson C
    Med Sci (Paris); 2005 Jan; 21(1):78-82. PubMed ID: 15639025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central statistical monitoring: detecting fraud in clinical trials.
    Pogue JM; Devereaux PJ; Thorlund K; Yusuf S
    Clin Trials; 2013 Apr; 10(2):225-35. PubMed ID: 23283577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proposal and prototype for a Research Risk Repository to improve the protection of research participants.
    Rid A; Wendler D
    Clin Trials; 2011 Dec; 8(6):705-15. PubMed ID: 21859783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.